Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
133.7 USD +2.32% Intraday chart for Sarepta Therapeutics, Inc. +3.80% +38.61%
02/05 Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says MT
02/05 UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
BU
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating
MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M
MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours
MT
Transcript : Sarepta Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
Sarepta Therapeutics: Q1 Earnings Snapshot
AQ
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
BU
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
BU
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
FDA greenlights Italfarmaco's drug for rare muscular dystrophy
RE
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
AQ
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. News Sarepta Therapeutics, Inc.